The objective: of our study was to evaluate the effectiveness of therapy of chronic pelvic pain (CPP) in women with pelvic varicose veins (PVV). Patients and methods. The study involved 62 women of reproductive age with CPP and PVV. Patients have received Normoven («Kyiv Vitamin Factory») in a dose 500 mg 2 times a day per os courses of 14 days each month for six months. To prevent recurrence of pain 30 women were prescribed the same drug prophylactically during 3 months after the basic course with repetition after 3 months. 32 patients did not receive Normoven as an prevention. The control group consisted of 30 healthy women. All women conducted clinical and laboratory examination, ultrasound and Doppler to determine the internal diameter ovaric, uterine, arcuate and internal iliac veins (cm), and the definition of peak systolic velocity of blood flow in the uterine veins (cm/s). Pain was assessed by Pain Assessment Scales. The resulting digital material were treated statistically using the program Microsoft Excel 2000 and Statistica 5.11. Results. We found that most of women were limited their daily activities, half have had sleep disorders, almost half was depressed, emotional lability with frequent changes of mood was observed in 79.0%, and a third of women were in depression. Most women feel cramping, aching and tender of pain of moderate intensity (82.2%). After 6 months of treatment with Normoven we noticed complete reduction of pain in 67.7% of women, in most women improved sleep, mood and normalization of daily activities. One-third of patients remained periodic light intensity pain. There was a significant decrease in pain intensity (p<0.05), which accoding to VAS score was 1.50±1.3 points. Conclusions. Periodic preventive courses of Normoven allowed to prevent recurrence of congestive pelvic syndrome and pelvic pain in 90.0% of patients. Key words: chronic pelvic pain, varicose veins of the pelvis, Normoven.